Comparative Pharmacology
Head-to-head clinical analysis: CYANOKIT versus VALNAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYANOKIT versus VALNAC.
CYANOKIT vs VALNAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxocobalamin, a form of vitamin B12, acts as a scavenger of cyanide ions by binding with them to form cyanocobalamin, which is then excreted in urine. It has a higher affinity for cyanide than cytochrome c oxidase, thereby restoring mitochondrial function.
Valproate semisodium (valproic acid derivative) increases GABA levels in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, and modulates voltage-gated sodium channels and T-type calcium channels. The combination (valproate semisodium) dissociates in the gastrointestinal tract to valproic acid and sodium valproate, providing rapid absorption and sustained release.
5 g intravenous infusion over 15 minutes for adults and pediatric patients weighing >=40 kg. A second dose of 5 g may be administered if needed based on clinical response.
Adults: 650 mg orally twice daily, with a maximum of 1300 mg per day.
None Documented
None Documented
The terminal elimination half-life of hydroxocobalamin is approximately 24-28 hours in healthy adults; in cyanide poisoning, the half-life may be prolonged due to reversible binding to cyanide.
3-5 hours (healthy adults). In severe renal impairment (CrCl <30 mL/min), half-life extends to 12-24 hours, increasing risk of accumulation and toxicity.
Primarily renal elimination as hydroxocobalamin and cyanocobalamin; >90% of an intravenous dose is excreted in urine within 72 hours, with the remainder eliminated in feces via biliary excretion.
Primarily renal (90% unchanged drug), with 10% biliary-fecal. In renal impairment, half-life prolongs significantly, requiring dose adjustment.
Category C
Category C
Antidote
Antidote